Silence Therapeutics Technology Licensee Quark Pharmaceuticals announces First Patient Dosed in Phase 3 Clinical Trial for Acute Kidney Injury

Silence Therapeutics plc, AIM:SLN (“Silence” or “the Company”) a leader in the discovery, delivery and
development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need,
notes Quark Pharmaceutical, Inc’s (“Quark”) press release “Quark Pharmaceuticals, Inc Announces First
Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac
Surgery”. Quark also reported that they have reached agreement with the FDA on the overall Phase 3 trial
design with a new primary endpoint.

Quark holds a licence to Silence’s chemical modification technology. Silence is eligible to receive either
approximately 1.5%-4% royalties from Quark (on QPI-1002) plus milestones, or 15% of the clinical,
regulatory and commercial milestone payments and royalties received by Quark from its partner Novartis.

Read More

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...